Skip to main content
SpringerLink
Log in

Pharmacology and Therapeutic Use of Calcitonin

  • Special Drug Evaluations
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Calcitonin1 is a peptide hormone secreted by the C-cells of the thyroid gland. A major physiological function of the hormone appears to be the protection of the skeleton against resorption in humans. It thus opposes the resorptive actions of parathyroid hormone and 1,25 dihydroxyvitamin D.

This action is utilised pharmacologically in order to treat diseases where increased bone resorption is a major component. The efficacy of calcitonin in the treatment of Paget s disease of bone is well established, especially as it is currently the most effective agent in the treatment of the osteolytic form of the disease. In other bone diseases where resorption of bone is a component it is likely to be worthy of a trial of therapy. There are also sound theoretical reasons why calcitonin may be of benefit in the treatment of certain osteoporoses, especially in combination with other agents. Most recent studies would seem to support this view.

A disadvantage of calcitonin therapy is that the hormone has to be administered paren-terally, although future developments may obviate this. It is, however, a form of treatment which is free of any long term serious side effects, and calcitonin now has a definite place in the management of specific bone and calcium disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Acquaviva, P.C.; Eisinger, J.; Schiano, A. and Serratrice, G.: Calcitonin and algodystrophy: A review of 90 patients; in Kanis (Ed) Bone Disease and Calcitonin, pp. 143–148 (Armour Pharmaceutical Company Ltd, Eastbourne 1977).

    Google Scholar 

  • Aliapoulios, M.A. and Munson, P.L.: Thyrocalcitonin. Surgical Forum 16: 55–57 (1965).

    PubMed  CAS  Google Scholar 

  • Altman, R.D.; Johnston, C.C.; Khairi, M.R.A.; Wellman, H.; Serafini, A.N. and Sankey, R.R.: Influence of disodium etidronate on clinical and laboratory manifestations of Paget’s disease of bone (osteitis deformans). New England Journal of Medicine 289: 1379–1384(1973).

    Article  PubMed  CAS  Google Scholar 

  • August, G.P.; Shapiro, J. and Hung, W.J.: Calcitonin therapy of children with osteogenesis imperfecta. Journal of Paediatrics 91: 1001–1005 (1977).

    Article  CAS  Google Scholar 

  • Baud, C.A.; De Siebenthal, J.; Langer, B.; Tupling, M.R. and Mach, R.S.: The effects of prolonged administration of thyrocalcitonin in human senile osteoporosis; in Taylor (Ed) Calcitonin 1969 — Proceedings of the 2nd International Symposium, pp.540–546 (Heinemann, London 1970).

    Google Scholar 

  • Bijvoet, O.L.M. and Jansen, A.P.: Thyrocalcitonin in Paget’s disease. Lancet 2: 471–472 (1967).

    Article  Google Scholar 

  • Bijvoet, O.L.M.; Hosking, D.J.; Frijlink, W.B.; Te Velde, J. and Vellenga, C.J.L.R.: Treatment of Paget’s disease with combined calcitonin and diphosphonate (EHDP). Metabolic Bone Disease and Related Research 1: 251–261 (1978).

    Article  Google Scholar 

  • Blanco, O.; Stivel, M.; Mautalen, C. and Schajowicz, F J.: Familial idiopathic hyperphosphatasia. Journal of Bone and Joint Surgery 59-B: 421–427 (1977).

    PubMed  CAS  Google Scholar 

  • Bowie, H.I.C. and Kanis, J.A.: Calcitonin in the assessment and preparation of patients with Paget’s disease for surgery; in Kanis (Ed) Bone Disease and Calcitonin, pp.61–69 (Armour Pharmaceutical Company Ltd, Eastbourne 1977).

    Google Scholar 

  • Briskin, A.I.; Dubrov, E.Y. and Strizhakova, L.L.: Efficacy of thyrocalcitonin in the treatment of steroid osteoporosis. Klinicheskara Meditsina (Moskva) 54: 80–84 (1976).

    CAS  Google Scholar 

  • Brown, P.; Thin, C.G.; Malone, D.N.S.; Roscoe, P. and Strong, J.A.: Metabolic studies with porcine calcitonin in osteoporosis. Scottish Medical Journal 15: 207–212 (1970).

    PubMed  CAS  Google Scholar 

  • Caniggia, A.; Gennari, C; Bencini, M.; Cesari, L. and Borrello, G.: Calcium metabolism and 47calcium kinetics before and after long-term thyrocalcitonin treatment in senile osteoporosis. Clinical Science 38: 397–407 (1970).

    CAS  Google Scholar 

  • Caniggia, A. and Gennari, C: Calcitonin treatment in Ekman-Lobstein disease. Calcified Tissue Research 9: 243–244 (1972).

    Article  PubMed  CAS  Google Scholar 

  • Cantalamessa, L; Catania, A.; Reschini, E. and Peracchi, M.: Inhibitory effect of calcitonin on growth hormone and insulin secretion in man. Metabolism 27: 987–992 (1978).

    Article  PubMed  CAS  Google Scholar 

  • Castells, S.; Lu, C; Baker, R.K. and Wallach, S.: Effects of synthetic salmon calcitonin in osteogenesis imperfecta. Current Therapeutic Research 16: 1–14 (1974).

    PubMed  CAS  Google Scholar 

  • Cohn, S.H.; Dombrowski, C.S.; Hauser, W.; Klopper, J. and Atkins, H.L.: Effects of porcine calcitonin on calcium metabolism in osteoporosis. Journal of Clinical Endocrinology and Metabolism 33: 719–728 (1971).

    Article  PubMed  CAS  Google Scholar 

  • Cooper, C.W.; Obie, J.F.; Toverud, S.U. and Munson, P.L.: Elevated serum calcitonin and serum calcium during suckling in the baby rat. Endocrinology 101: 1657–1664 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Dambacher, M.A.; Olah, A.J.; Guncaga, J.; Lentner, C. and Haas, H.G.: Calcitonin in human osteoporosis. Results of prolonged administration, assessed by metabolic balance and quantitative histological techniques. Israel Journal of Medical Sciences 7: 366(1971).

    PubMed  CAS  Google Scholar 

  • De Bastiani, G.; Nogarin, L. and Perusi, M.: Pig calcitonin in the treatment of localised osteoporosis. Italian Journal of Orthopaedics and Traumatology 2: 181–190 (1976).

    PubMed  Google Scholar 

  • De Luise, M.; Martin, T.J. and Melick, R.A.: Inactivation and degradation of porcine calcitonin by rat liver, and relative stability of salmon calcitonin. Journal of Endocrinology 48: 181–188 (1970a).

    Article  Google Scholar 

  • De Luise, M.; Martin, T.J. and Melick, R.A.: Tissue distribution of calcitonin in the rat — comparison with parathyroid hormone. Journal of Endocrinology 53: 475–482 (1972).

    Article  PubMed  Google Scholar 

  • De Rose, J.; Singer, F.R.; Avramides, A.; Flores, A.; Dziadiw, R.; Baker, R.K. and Wallach, S.: Response of Paget’s disease to porcine and salmon calcitonins. American Journal of Medicine 56: 858–866 (1974).

    Article  Google Scholar 

  • Dietrich, F.M. and Fischer, J.A.: Immunological studies with synthetic human calcitonin; in MacIntyre (Ed) Human Calcitonin and Paget’s Disease, pp.179–194 (Hans Huber, Bern 1977).

    Google Scholar 

  • Dietrich, F.M.; Fischer, J.A. and Bijvoet, O.L.: Formation of antibodies to synthetic human calcitonin during treatment of Paget’s disease. Acta Endocrinologica Scandinavica 92: 468–476(1979).

    CAS  Google Scholar 

  • Douglas, D.L.; Duckworth, T.; Russell, R.G.G.; Kanis, J.A.; Preston, C.J.; Preston, F.E.; Prenton, M.A. and Woodhead, J.S.: Effect of dichloromethylene diphosphonate in Paget’s disease of bone and in hypercalcaemia due to primary hyper-parathyroidism or malignant disease. Lancet 1: 1043–1047 (1980).

    Article  PubMed  CAS  Google Scholar 

  • Dunn, V.; Condon, V.R. and Rallison, M.L.: Familial hyperphosphatasemia: Diagnosis in early infancy and response to human thyrocalcitonin therapy. American Journal of Roentgenology 132: 541–545(1979).

    PubMed  CAS  Google Scholar 

  • Eisman, J.A.; Maclntyre, I.; Findlay, D.M.; Michelangeli, V.P.; Moseley, J.M.; Partridge, N.C. and Martin, T.J.: ‘Calcitonin and 1,2 5-dihydroxy vitamin D receptors in human breast cancer cells. Journal of Endocrinology. In press (1980).

  • Evans, I.M.A.; Doyle, F.H.; Banks, L.; Pennock, J.; Joplin, G.F. and Maclntyre, I.: Paget’s disease: Results of long-term treatment with synthetic human calcitonin; in Maclntyre and Szelke (Eds) Molecular Endocrinology, pp.235–242 (Elsevier/North Holland Biomedical Press, Amsterdam 1977).

    Google Scholar 

  • Evans, IM.A.; Banks, L.; Doyle, F.H.; Joplin, CF.; Pennock, J.; Stevenson, J.C. and Maclntyre, I.: Paget’s disease of bone: the effect of stopping long term human calcitonin and recommendations for future treatment. Metabolic Bone Disease and Related Research 2: 87–91 (1980).

    Article  Google Scholar 

  • Fahrenkrug, J.; Hornum, I. and Rehfeld, J.F.: Effect of calcitonin on serum gastrin concentration and component pattern in man. Journal of Clinical Endocrinology and Metabolism 41: 149–152(1975).

    Article  PubMed  CAS  Google Scholar 

  • Foster, G.V.; Clark, MB.; Williams, G; Nathanson, B.M.; Horton, R.; Buranapong, P. and Glass, H.I.: Metabolic fate of human calcitonin in the dog; in Taylor (Ed) Endocrinology 1971, pp.71–78 (Heinemann, London 1972).

    Google Scholar 

  • Foster, G.V.; Maclntyre, I. and Pearse, A.G.E.: Calcitonin production and the mitochondrion-rich cells of the dog thyroid. Nature 203: 1029–1030 (1964).

    Article  PubMed  CAS  Google Scholar 

  • Foster, G.V.; Doyle, F.H.; Bordier, P. and Matrajt, H.: Effects of thyrocalcitonin on bone. Lancet 2: 1428–1431 (1966).

    Article  PubMed  CAS  Google Scholar 

  • Foster, G.V.; Doyle, F.H.; Bordier, P. and Matrajt, H.: In vivo effect of thyrocalcitonin on bone; in Milhaud et al. (Eds) Les Tissus Calcifies, Ve Symposium Europeen, pp. 173–177 (Societé d’Edition d’Enseignement Superieur, Paris 1969).

    Google Scholar 

  • Friedman, J. and Raisz, L.G.: Thyrocalcitonin: inhibitor of bone resorption in tissue culture. Science 150: 1465–1466 (1965).

    Article  PubMed  CAS  Google Scholar 

  • Frijlink, N.B.; Bijvoet, O.L.M.; Te Velde, J. and Heynen, G.: Treatment of Paget’s disease with (3-amino-l-hydroxy-propylidene)-l, 1-bisphosphonate (A.P.D.). Lancet 1: 799–803(1979).

    Article  PubMed  CAS  Google Scholar 

  • Galante, L.S.; Colston, K.W.; MacAuley, S.J. and Maclntyre, I.: Effect of calcitonin on vitamin D metabolism. Nature 288: 271–273(1972).

    Article  Google Scholar 

  • Garel, J.-M. and Barlet, J.-P.: Calcitonin in the mother, foetus and newborn. Annales de Biologie Animale, Biochimie, Biophysique 18: 53–68 (1978).

    Article  CAS  Google Scholar 

  • Gray, T.K.; Bieberdorf, F.A. and Fordtran, J.S.: Thyrocalcitonin and the jejunal absorption of calcium, water and electrolytes in normal subjects. Journal of Clinical Investigation 52: 3084–3088 (1973).

    Article  PubMed  CAS  Google Scholar 

  • Greenberg, P.B.; Martin, T.J.; Melick, R.A.; Jablonski, P. and Watts, J. McK.: Calcitonin clearance in the pig and in the isolated perfused pig liver. Journal of Endocrinology 54: 125–135 (1972).

    Article  PubMed  CAS  Google Scholar 

  • Gudmundsson, T.V.; Maclntyre, I. and Soliman, H.A.: The isolation of thyrocalcitonin and a study of its effects in the rat. Proceedings of the Royal Society of London Series B 164: 460–478(1966).

    Article  CAS  Google Scholar 

  • Haas, H.G.; Dambacher, M.A.; Guncaga, J. and Lauffenburger, T.: Renal effects of calcitonin and parathyroid extract in man. Journal of Clinical Investigation 50: 2689–2702 (1971).

    Article  PubMed  CAS  Google Scholar 

  • Habener, J.F.; Singer, F.R.; Neer, RM.; Deftos, L.J, and Potts, J.T.: Metabolism of salmon and porcine calcitonin: an explanation for the increased potency of salmon calcitonin; in Talmage and Munson (Eds) Calcium, Parathyroid Hormone and the Calcitonins, pp. 152–156 (Excerpta Medica, Amsterdam 1972).

    Google Scholar 

  • Hantman, DA.; Vogel, J.M.; Donaldson, C.L.; Friedman, R.; Goldsmith, R.S. and Hulley, S.B.: Attempts to prevent disuse osteoporosis by treatment with calcitonin, longitudinal compression and supplementary calcium and phosphorus. Journal of Clinical Endocrinology and Metabolism 36: 845–858 (1973).

    Article  PubMed  CAS  Google Scholar 

  • Hesch, R.-D.; Hüfner, M.; Hasenjäger, M.; Mühlen, A. and Creutzfeldt, W.: Inhibition of gastric secretion by calcitonin. Acta Endocrinologica Scandinavica Supplementum 155: 216 (1971).

    Google Scholar 

  • Hillyard, C.J.; Stevenson, J.C. and Maclntyre, I,: Relative deficiency of plasma-calcitonin in normal women. Lancet 1: 961–962(1978).

    Article  PubMed  CAS  Google Scholar 

  • Hioco, D.; Bordier, P.L.; Miravet, L.; Denys, H. and Tun-Chot, S.: Prolonged administration of calcitonin in man: biological, isotopic and morphological effect; in Taylor (Ed) Calcitonin 1969 — Proceedings of the 2nd International Symposium, pp.514–522 (Heinemann, London 1970).

    Google Scholar 

  • Horwith, M.; Suh, S.M.; Torun, B.; Viteri, F.; Maclntyre, I.; Whalen, J.P.; Mena, E.; Nunez, E.; Eisenberg, E. and Krook, L.: Synthetic human calcitonin in the treatment of hereditary bone dysplasia (hyperphosphatasaemia); in Maclntyre (Ed) Human Calcitonin and Paget’s Disease, pp.207–215 (Hans Huber, Bern 1977).

    Google Scholar 

  • Illig, R.; Budliger, H.; Kind, H.-P.; Fanconi, A. and Prader, A.: Effects of synthetic human, porcine and salmon calcitonin on calcium and phosphorus in immobilized children. Helvetia Paediatrica Acta 27: 225–238 (1972).

    CAS  Google Scholar 

  • Jowsey, J.; Riggs, B.L.; Goldsmith, R.S.; Kelly, P.J. and Arnaud, G: Effects of prolonged administration of porcine calcitonin in postmenopausal osteoporosis. Journal of Clinical Endocrinology and Metabolism 33: 752–758 (1971).

    Article  PubMed  CAS  Google Scholar 

  • Jowsey, J.; Riggs, B.L.; Kelly, P.J. and Hoffman, D.L.: Calcium and salmon calcitonin in treatment of osteoporosis. Journal of Clinical Endocrinology and Metabolism 47: 633–639 (1978).

    Article  PubMed  CAS  Google Scholar 

  • Khairi, M.R.A.; Johnston, C.C.; Altman, R.D., Wellman, H.N; Serafini, A.N. and Sankey, R.R.: Treatment of Paget’s disease of bone (osteitis deformans). Results of a one-year study with sodium etidronate. Journal of the American Medical Association 230: 562–567 (1974).

    Article  PubMed  CAS  Google Scholar 

  • Klein, D.C. and Raisz, L.G.: Role of adenosine 3′5′-monophos-phate in the hormonal regulation of bone resorption: Studies with cultured fetal bone. Endocrinology 89: 818–826 (1971).

    Article  PubMed  CAS  Google Scholar 

  • Larkins, R.G.; MacAuley, S.J.; Colston, K.W.; Evans, I.M.A., Galante, L.S. and Maclntyre, I.: Regulation of vitamin-D metabolism without parathyroid hormone. Lancet 2: 289–291 (1973).

    Article  PubMed  CAS  Google Scholar 

  • Leicht, E.; Biro, G. and Weinges, K.F.: Inhibition of releasing-hormone induced secretion of TSH and LH by calcitonin. Hormone and Metabolic Research 6: 410–414(1974).

    Article  PubMed  CAS  Google Scholar 

  • Lorenc, R.; Tanaka, Y.; DeLuca, H.F. and Jones, G.: Lack of effect of calcitonin on the regulation of vitamin D metabolism in the rat. Endocrinology 100: 468–472 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Maclntyre, I.: The action and control of the calcium-regulating hormones. Journal of Endocrinological Investigation 1: 277–284(1978).

    Google Scholar 

  • Maclntyre, I.; Parsons, J.A. and Robinson, C.J.: The effect of thyrocalcitonin on blood-bone calcium equilibrium in the perfused tibia of the cat. Journal of Physiology (London) 191: 393–405(1967).

    Google Scholar 

  • Maclntyre, I.; Evans, I.M.A. and Woodhouse, N.J.Y.: Paget’s disease; in DeGroot et al. (Eds) Endocrinology Vol. 2, pp.891–900 (Grune and Stratton, New York 1979).

    Google Scholar 

  • Maclntyre, I.; Evans, I.M.A.; Hobitz, H.H.G.; Joplin, G.F. and Stevenson, J.C.: Calcitonin: chemistry, physiology and therapeutic applications. Arthritis and Rheumatism. In press (1980).

  • Marcus, R.; Heersche, J.N.M. and Aurbach, G.D.: Effects of calcitonin on formation of 3′5′-cyclic AMP in bone and kidney. 53rd Annual Meeting of United States Endocrine Society: Abstract No. 57 (1971).

  • Martin, T.J.; Robinson, C.J. and Maclntyre, I.: The mode of action of thyrocalcitonin. Lancet 1: 900–902(1966).

    Article  PubMed  CAS  Google Scholar 

  • Martin, T.J.; Hunt, N.H.; Ellison, M.; Underwood, J.C.E. and Michelangeli, V.P.: Physiology and biochemical pharmacology of calcitonin action; in Maclntyre and Szelke (Eds) Molecular Endocrinology, pp.179–192 (Elsevier/North Holland Biomedical Press, Amsterdam 1977).

    Google Scholar 

  • Martin, T.J. and Woodhouse, N.J.Y.: Calcitonin in the treatment of Paget’s disease; in Kanis (Ed) Bone Disease and Calcitonin, pp.11–24 (Armour Pharmaceutical Company Ltd, Eastbourne 1977).

    Google Scholar 

  • Martin, T.J.: The therapeutic uses of calcitonin. Scottish Medical Journal 23: 161–165 (1978).

    PubMed  CAS  Google Scholar 

  • Marx, S.J.; Woodard, C.J. and Aurbach, G.D.: Calcitonin receptors of kidney and bone. Science 178: 999–1001 (1972).

    Article  PubMed  CAS  Google Scholar 

  • McCredie, D.A.; Dixon, S.R.; Martin, T.J.; Melick, R.A.; Roten-berg, E. and Shipman, R.: The effects of calcitonin in children in health and disease; in Proceedings of the XIII International Congress of Paediatrics, pp.155–161 (Verlag der Weiner Medizinischen Akademie, Vienna 1971).

  • Melick, R.A.; Martin, T.J. and Storey, E.: Use of porcine calcitonin in osteoporosis. Australia and New Zealand Journal of Medicine 3: 285–289(1973).

    Article  CAS  Google Scholar 

  • Milhaud, G.; Perault, A.M. and Moukhtar, M.S.: Etude de mecanisme de l’action hypocalcemiante de la thyrocalcitonine. Comptes Rendus — Academie des Sciences (Paris) 261: 813–816(1965).

    CAS  Google Scholar 

  • Milhaud, G. and Hankiss, J.: Inactivation de la thyrocalcitonine par divers organes. Comptes Rendus — Academie des Sciences (Paris) 268: 124–127 (1969).

    CAS  Google Scholar 

  • Milhaud, G.; Talbot, J.N. and Coutris, G.: Calcitonin treatment of postmenopausal osteoporosis. Evaluation of efficacy by principal components analysis. Biomedicine 22: 223–232 (1975).

    PubMed  CAS  Google Scholar 

  • Nagant de Deuxchaisnes, C; Dercq, J.P.; Devogelaer, J.P.; Huaux, J.P. and Rombouts-Lindemans, C: Traitment de la maladie de Paget au moyen d’immunosuppresseurs et de mithramycine; in Hioco (Ed) La Maladie de Paget, pp.228–231 (Armour Montagu, Paris 1974).

    Google Scholar 

  • Nagant de Deuxchaisnes, C; Rombouts-Lindemans, C; Huaux, J.P.; Devogelaer, J.P.; Malghem, J. and Maldague, B: Roentgenologic evaluation of the action of the diphosphonate EHDP and of combined therapy (EHDP and calcitonin) in Paget’s disease of bone; in Maclntyre and Szelke (Eds) Molecular Endocrinology Vol. 1, pp.405–433 (Elsevier/North Holland Biomedical Press, Amsterdam 1979).

    Google Scholar 

  • Nilsson, O.; Almqvist, S. and Karlberg, B.E.: Salmon calcitonin in the acute treatment of moderate and severe hypercalcaemia in man. Acta Medica Scandinavica 204: 249–252 (1978).

    Article  PubMed  CAS  Google Scholar 

  • Palmieri, G.M.A.; Dvorak, J. and Bottomley, R.: Calcitonin in steroid-induced osteoporosis. New England Journal of Medicine 290: 1490–1491 (1974).

    Article  PubMed  CAS  Google Scholar 

  • Pearse, A.G.E.: The cytochemistry of the thyroid C-cells and their relationship to calcitonin. Proceedings of the Royal Society of London Series B 164: 478–487 (1966).

    Article  CAS  Google Scholar 

  • Peck, W.A.; Wilkins, J.; Dowling, I. and Carpenter, J.: Preferential responses of periosteal cell cyclic AMP to calcitonin and of bone cell cyclic AMP to parathyroid hormone, and failure of 1,25 dihydroxyvitamin D3 to modify the effects of parathyroid hormone; in Abstracts of 2nd International Workshop on Calcified Tissues, p.27 (Israel 1976).

  • Petralito, A.; Lunetta, M.; Liuzzo, A.; Fiore, C.E. and Heynen, G.: Effects of salmon calcitonin on blood glucose and insulin levels under basal conditions and after intravenous glucose load. Journal of Endocrinological Investigation 2: 209–211 (1979).

    PubMed  CAS  Google Scholar 

  • Raisz, L.G.: Bone resorption in tissue culture. Factors influencing the response to parathyroid hormone. Journal of Clinical Investigation 44: 103–116(1965).

    Article  PubMed  CAS  Google Scholar 

  • Rasmussen, H.; Bordier, P.; Marie, D.; Auquier, L.; Eisinger, JR.; Kuntz, D.; Caulin, F.; Argemi, B.; Gueris, J. and Julien, A.: Effect of combined therapy with phosphate and calcitonin on bone volume in osteoporosis. Metabolic Bone Disease and Related Research 2: 107–111 (1980).

    Article  CAS  Google Scholar 

  • Reynolds, J.J.; Dingle, J.T.; Gudmundsson, T.V. and Maclntyre, I.: Bone resorption in vitro and its inhibition by calcitonin; in Taylor (Ed) Calcitonin: Proceedings of the Symposium on Thyrocalcitonin and the C cells, pp.223–229 (Heinemann, London 1968).

    Google Scholar 

  • Rittel, W.; Maier, R.; Brugger, M.; Kamber, B., Riniker, B. and Sieber, P.: Struktur-Wirkungsbeziehungen beim menschlichen calcitonin — III. Die biologische Aktivität verkürzter oder an den Katten modifizierter, synthetischer Analoger. Experientia 32: 246–248 (1976).

    Article  PubMed  CAS  Google Scholar 

  • Rittel, W.: The chemistry of human calcitonin; in Maclntyre (Ed) Human Calcitonin and Paget’s Disease, pp.23–32 (Hans Huber, Bern 1977).

    Google Scholar 

  • Robinson, C.J.; Martin, T.J.; Matthews, E.W. and Maclntyre, I.: Mode of action of thyrocalcitonin. Journal of Endocrinology 39: 71–79(1967).

    Article  PubMed  CAS  Google Scholar 

  • Robinson, C.J.; Matthews, E.W. and Maclntyre, I.; The effect of parathyroid hormone and thyrocalcitonin on the intestinal absorption of calcium and magnesium; in Milhaud et al. (Eds) Les Tissus Calcifies, Ve Symposium Europeen, pp.279–282 (Societé d’Edition d’Enseignement Superieur, Paris 1969).

    Google Scholar 

  • Rosenberg, E.; Lang, R.; Boisseau, V.; Rojanasathir, S. and Avioli, L.V.: Effect of long-term calcitonin therapy on the clinical course of osteogenesis imperfecta. Journal of Clinical Endocrinology and Metabolism 44: 346–355 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Russell, R.G.G.; Smith, R.; Preston, C; Walton, R.J. and Woods, C.G.: Diphosphonates in Paget’s disease. Lancet 1: 894–898 (1974).

    PubMed  CAS  Google Scholar 

  • Ryan, W.G.: Treatment of Paget’s disease of bone with mithramycin. Clinical Orthopaedics and Related Research 127: 106–110(1977).

    PubMed  Google Scholar 

  • Samaan, N.A.; Anderson, G.D. and Adam-Mayne, M.E.: Immunoreactive calcitonin in the mother, neonate, child and adult. Amer. J. Obstet. Gynecol. 121: 622–625 (1975).

    CAS  Google Scholar 

  • Seiber, P.; Brugger, M.; Kamber, B.; Riniker, B.; Rittel, M.; Maier, R. and Staehlin, M.: Synthesis and biological activity of peptide sequences related to porcine α-thyrocalcitonin; in Taylor (Ed) Calcitonin 1969, Proceedings of the 2nd International Symposium, pp.28–33 (Heinemann, London 1970).

    Google Scholar 

  • Shai, F.; Baker, R.K. and Wallach, S.: The clinical and metabolic effects of porcine calcitonin on Paget’s disease of bone. Journal of Clinical Investigation 50: 1927–1940 (1971).

    Article  PubMed  CAS  Google Scholar 

  • Shiraki, M.; Ohyama, T.; Uchiyama, S.; Ito, H. and Orimo, H.: Therapeutic effect of porcine calcitonin in senile osteoporosis. Calcified Tissues Research 15: 162 (1974).

    CAS  Google Scholar 

  • Singer, F.R.; Woodhouse, N.J.Y.; Parkinson, D.K. and Joplin, G.F.. Some acute effects of administered porcine calcitonin in man. Clinical Science 37: 181–190 (1969).

    PubMed  CAS  Google Scholar 

  • Singer, F.R.; Rude, R.K. and Mills, B.G.: Studies of the treatment and aetiology of Paget’s disease of bone; in Maclntyre (Ed) Human Calcitonin and Paget’s Disease, pp.93–110 (Hans Huber, Bern 1977).

    Chapter  Google Scholar 

  • Singer, F.R.: Antibodies and clinical resistance to salmon calcitonin in patients with Paget’s disease of bone-, in Sixth International Congress of Endocrinology, Abstract No. 220 (Melbourne 1980).

  • Smith, R.; Russell, R.G.G. and Bishop, M.: Diphosphonates and Paget’s disease of bone. Lancet 1: 945–947 (1971).

    Article  PubMed  CAS  Google Scholar 

  • Stevenson, J.C.; Evans, I.M.A.; Colston, K.W.; Gwee, H.M. and Mashiter, K.: Serum-prolactin after subcutaneous human, calcitonin. Lancet 2: 711–712 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Stevenson, J.C.; Hillyard, C.J., Maclntyre, I.; Cooper, H. and Whitehead, M.I: A physiological role for calcitonin: protection of the maternal skeleton. Lancet 2: 769–770 (1979).

    Article  PubMed  CAS  Google Scholar 

  • Stevenson, J.C.: Calcitonin; in Duursma and Van der Sluys Veer (Eds) Osteoporose, pp.38–50 (Wetenschappelijke uitgeverij Bunge, Utrecht 1980a).

    Google Scholar 

  • Stevenson, J.C.. The structure and function of calcitonin. Investigative and Cell Pathology 3: 187–193 (1980b).

    CAS  Google Scholar 

  • Stevenson, J.C.; Hillyard, C.J.; Spanos, E.; Maclntyre, I.; Town-send, P.T., Whitehead, M.I. and Young, O.: The effect of oestrogen on calcitonin secretion in postmenopausal women. Journal of Endocrinology. In press (1980).

  • Talmage, R.V.; Grubb, S.A.; Norimatsu, H. and VanderWiel, C.J.: Evidence for an important physiological role for calcitonin. Proceedings of the National Academy of Sciences (USA) 77: 609–613(1980).

    Article  CAS  Google Scholar 

  • Thompson, J.S.; Palmieri, G.M.A., Eliel, L.P. and Crawford, R.L.: The effect of porcine calcitonin on osteoporosis induced by adrenal cortical steroids. Journal of Bone and Joint Surgery 54A: 1490–1500(1972).

    Google Scholar 

  • Van der Sluys Veer, J.; Bijvoet, O.L.M. and Smeenk, D.: Effects of long-term porcine calcitonin administration in patients with Paget’s disease or osteoporosis. Calcified Tissues Research: Supplement 88 (1970).

  • Wallach, S.; Cohn, S.H.; Atkins, H.L.; Ellis, K.J.; Kohberger, R.; Aloia, J.F. and Zanzi, I.: Effect of salmon calcitonin on skeletal mass in osteoporosis. Current Therapeutic Research 22: 556–572 (1977).

    Google Scholar 

  • Wong, G.L. and Cohn, D.V.: Target cells in bone for parathormone and calcitonin are different. Enrichment for each cell type by sequential digestion of mouse calvaria and selective adhesion to polymeric surfaces. Proceedings of the National Academy of Sciences (USA) 72: 3167–3171 (1975).

    Article  CAS  Google Scholar 

  • Woodhouse, N.J.Y.; Reiner, M.; Kalu, D.N.; Galante, L.; Leese, B.; Foster, G.V.; Joplin, G.F. and Maclntyre, I.: Some effects of acute and chronic calcitonin M administration in man; in Taylor (Ed) Calcitonin 1969, Proceedings of the 2nd International Symposium, pp.504–513 (Heinemann, London 1970).

    Google Scholar 

  • Woodhouse, N.J.Y.; Reiner, M., Bordier, P.; Kalu, D.N., Fisher, M.T.; Foster, G.V.; Joplin, G.F. and Maclntyre, I.: Human calcitonin in the treatment of Paget’s bone disease. Lancet 1: 1139–1143(1971).

    Article  PubMed  CAS  Google Scholar 

  • Woodhouse, N.J.Y.; Joplin, G.F.; Maclntyre, I. and Doyle, F.H.: Radiological regression in Paget’s disease treated by human calcitonin. Lancet 2: 992–994 (1972).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrine Unit, Royal Postgraduate Medical School, Hammersmith Hospital, Du Cane Road, London, W12 OHS, England

    John C. Stevenson &  Imogen M. A. Evans

Authors
  1. John C. Stevenson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Imogen M. A. Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stevenson, J.C., Evans, I.M.A. Pharmacology and Therapeutic Use of Calcitonin. Drugs 21, 257–272 (1981). https://doi.org/10.2165/00003495-198121040-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-198121040-00002

Keywords

Search

Navigation